Pharma Nord   Report issue

For profit Phase 3 Phase 4
Founded: Vejle Denmark (1981)
Status: No NME R&D (1981)

Organization Overview

First Clinical Trial
1998
NCT01819649
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Pharma Nord

Active Ingredients

Drugs in Phase 4 Trials (2)

glucosamine (1 trial)

ubiquinone (4 trials)

Drugs in Phase 3 Trials (3)

melatonin (2 trials)

saccharomyces cerevisiae (1 trial)

vitamin d3 (1 trial)

Drugs in Other Trials (4)

high-selenium yeast (2 trials)

icosapent ethyl (vascepa) (1 trial)

selenium (2 trials)

soybean oil (Intralipid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Breast Neoplasms (Phase 3)

Communicable Diseases (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Dyssomnias (Phase 3)

Infections (Phase 3)

Metabolic Syndrome (Phase 3)

Osteoarthritis (Phase 4)

Parasomnias (Phase 3)

Respiratory Tract Infections (Phase 3)

Sleep Wake Disorders (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 9